Advertisement

International Journal of Clinical Oncology

, Volume 24, Issue 6, pp 706–711 | Cite as

Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy

  • Aaron Dotson
  • Allison May
  • Facundo Davaro
  • Syed Johar Raza
  • Sameer Siddiqui
  • Zachary HamiltonEmail author
Original Article

Abstract

Background

Squamous cell carcinoma (SCC) of the bladder is a rare, aggressive malignancy. Unlike urothelial cell carcinoma, SCC is resistant to chemotherapy and guidelines recommend radical cystectomy (RC) without neoadjuvant chemotherapy (NAC). We aimed to evaluate the current management and survival of patients with invasive SCC treated with or without NAC.

Methods

671 patients with invasive SCC bladder cancer from 2004 to 2015 in the National Cancer Data Base were identified. Patients were stratified by treatment with RC alone or NAC prior to RC (NAC + RC). Survival analysis was performed with Kaplan–Meier and Cox regression. Secondary outcomes included length of stay and readmission.

Results

Of 671 patients, 92.8% were treated with RC alone and 7.2% with NAC + RC. Cox regression for mortality was performed including age, Charlson score, clinical stage, and NAC. Increased risk of mortality was noted with increasing age (OR 1.01, p = 0.023) and Charlson score of 1–3 (HR 1.58–1.68, p < 0.05). NAC did not confer survival advantage (HR 1.17, p = 0.46). On Kaplan–Meier analysis, the overall survival was equivalent (log-rank p = 0.804). Hospital stay and readmission were similar between RC and NAC + RC groups.

Conclusions

Analysis of a national tumor registry suggests a lack of overall survival benefit for NAC with localized, muscle invasive SCC of the bladder. Further research directed at chemotherapy regimens for SCC is needed to optimize treatment and improve survival outcomes.

Keywords

Bladder cancer Squamous cell cancer Cystectomy Neoplasm invasion 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ploeg M, Aben KKH, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27(3):289–293CrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRefGoogle Scholar
  3. 3.
    Heney NM (1992) Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin N Am 19(3):429–433Google Scholar
  4. 4.
    Philippe SE, Agarwal N, Bangs R et al (2017) Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15:1240–1267CrossRefGoogle Scholar
  5. 5.
    Vale CL (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48(2):202–205CrossRefGoogle Scholar
  6. 6.
    Koay EJ, Teh BS, Paulino AC et al (2011) A surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends. Cancer 117(23):5325–5333CrossRefGoogle Scholar
  7. 7.
    Billis A, Schenka AA, Ramos CC et al (2001) Squamous and/or glandular differentiation in urothelial carcinoma: prevalence and significance in transurethral resections of the bladder. Int Urol Nephrol 33:631–633CrossRefGoogle Scholar
  8. 8.
    Lagwinski N, Thomas A, Stephenson AJ et al (2007) Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 31(12):1777–1787CrossRefGoogle Scholar
  9. 9.
    Swanson DA, Liles A, Zagars GK (1990) Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol 143:37–40CrossRefGoogle Scholar
  10. 10.
    Porten SP, Willis D, Kamat AM (2014) Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol 24(5):517–523CrossRefGoogle Scholar
  11. 11.
    National Cancer. Database. (n.d.). https://www.facs.org/quality-programs/cancer/ncdb. Accessed 15 Jan 2018
  12. 12.
    Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383CrossRefGoogle Scholar
  13. 13.
    Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866CrossRefGoogle Scholar
  14. 14.
    Advanced Bladder Cancer Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–205CrossRefGoogle Scholar
  15. 15.
    Winquist E, Kirchner TS, Segal R et al (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171:561–569CrossRefGoogle Scholar
  16. 16.
    Serretta V, Pomara G, Piazza F et al (2000) Pure squamous cell carcinoma of the bladder in Western countries. Report on 19 consecutive cases. Eur Urol 37:85–89CrossRefGoogle Scholar
  17. 17.
    Khaled HM, Shafik HE, Zabhloul MS et al (2014) Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation. Clin Genitourin Cancer 12(5):233–240CrossRefGoogle Scholar
  18. 18.
    Kassouf W, Spiess PE, Siefker-Radtke A et al (2007) Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder. Cancer 110:764–769CrossRefGoogle Scholar
  19. 19.
    Wishnow KI, Dmochowski R (1988) Pelvic recurrence after radical cystectomy without preoperative radiation. J Urol 140:42–43CrossRefGoogle Scholar
  20. 20.
    Scosyrev E, Yao J, Messing E (2009) Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology 73:822–827CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Division of Urology, Department of SurgerySaint Louis UniversitySt. LouisUSA

Personalised recommendations